These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31254645)

  • 1. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
    Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
    Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors.
    Negrete M; Romero-Ben E; Gutiérrez-Valencia A; Rosales-Barrios C; Alés E; Mena-Barragán T; Flores JA; Castillejos MC; de la Cruz-Ojeda P; Navarro-Villarán E; Cepeda-Franco C; Khiar N; Muntané J
    ACS Appl Bio Mater; 2021 Jun; 4(6):4789-4799. PubMed ID: 35007028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
    Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
    Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
    [No Abstract]   [Full Text] [Related]  

  • 5. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
    Varshosaz J; Raghami F; Rostami M; Jahanian A
    J Liposome Res; 2019 Dec; 29(4):383-398. PubMed ID: 30668221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
    Duan W; Liu Y
    Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
    Cai M; Li B; Lin L; Huang J; An Y; Huang W; Zhou Z; Wang Y; Shuai X; Zhu K
    Biomater Sci; 2020 Jun; 8(12):3485-3499. PubMed ID: 32432234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of Avocado Seed Extract Using Novel Charge-Switchable Mesoporous Silica Nanoparticles with Galactose Surface Modified to Target Sorafenib-Resistant Hepatocellular Carcinoma.
    Basu A; Sae-Be A; Namporn T; Suriyaphan O; Sithisarn P; Leanpolchareanchai J; Plommaithong P; Chatsukit A; Sa-Ngiamsuntorn K; Naruphontjirakul P; Ruenraroengsak P
    Int J Nanomedicine; 2024; 19():10341-10365. PubMed ID: 39430309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study.
    Zaafar D; Khalil HMA; Elkhouly GE; Sedeky AS; Ahmed YH; Khalil MG; Abo-Zeid Y
    Drug Deliv Transl Res; 2024 Nov; 14(11):3089-3111. PubMed ID: 38430357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
    Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
    Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galactosylated TPGS Micelles for Docetaxel Targeting to Hepatic Carcinoma: Development, Characterization, and Biodistribution Study.
    Tekchandani P; Kurmi BD; Paliwal R; Paliwal SR
    AAPS PharmSciTech; 2020 Jun; 21(5):174. PubMed ID: 32548786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
    Su Y; Wang K; Li Y; Song W; Xin Y; Zhao W; Tian J; Ren L; Lu L
    Nanomedicine (Lond); 2018 May; 13(9):1009-1023. PubMed ID: 29630448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
    Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
    Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
    Zhang W; Cai J; Wu B; Shen Z
    J Biomater Appl; 2019 Aug; 34(2):219-228. PubMed ID: 31084233
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
    Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma.
    Li Z; Ye L; Liu J; Lian D; Li X
    Int J Nanomedicine; 2020; 15():1469-1480. PubMed ID: 32184599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
    Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
    Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
    Bian Y; Guo D
    Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.